메뉴 건너뛰기




Volumn 43, Issue 3, 2011, Pages 833-836

A comparison of mycophenolate mofetil with mycophenolate sodium in renal transplant recipients on tacrolimus-based treatment

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; BASILIXIMAB; COTRIMOXAZOLE; ISONIAZID; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

EID: 79954514848     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.01.096     Document Type: Conference Paper
Times cited : (10)

References (15)
  • 1
    • 69149096137 scopus 로고    scopus 로고
    • Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation
    • T. Rath, and M. Kpper Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation Transplant Proc 41 2009 2524
    • (2009) Transplant Proc , vol.41 , pp. 2524
    • Rath, T.1    Kpper, M.2
  • 2
    • 1342346699 scopus 로고    scopus 로고
    • Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients
    • M. Salvadori, H. Holzer, and A. de Mattos Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients Am J Transplant 4 2004 231
    • (2004) Am J Transplant , vol.4 , pp. 231
    • Salvadori, M.1    Holzer, H.2    De Mattos, A.3
  • 3
    • 27144546807 scopus 로고    scopus 로고
    • Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium
    • N. Kamar, L. Oufroukhi, and P. Faure Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium Nephrol Dial Transplant 20 2005 2231
    • (2005) Nephrol Dial Transplant , vol.20 , pp. 2231
    • Kamar, N.1    Oufroukhi, L.2    Faure, P.3
  • 4
    • 1642282715 scopus 로고    scopus 로고
    • Enteric-coated mycophenolate sodium: Therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients
    • H. Sollinger Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients Transplant Proc 36 2 suppl 2004 517S
    • (2004) Transplant Proc , vol.36 , Issue.2 SUPPL.
    • Sollinger, H.1
  • 5
    • 0035671418 scopus 로고    scopus 로고
    • Enteric coating of mycophenolate sodium: A rational approach to limit topical gastrointestinal lesions and extend the therapeutic index of mycophenolate
    • I. Bjarnason Enteric coating of mycophenolate sodium: a rational approach to limit topical gastrointestinal lesions and extend the therapeutic index of mycophenolate Transplant Proc 33 2001 3238
    • (2001) Transplant Proc , vol.33 , pp. 3238
    • Bjarnason, I.1
  • 6
    • 34249075713 scopus 로고    scopus 로고
    • MMF to EC-MPS conversion: What makes the difference?
    • H. Schmidt, and J. Brockmann MMF to EC-MPS conversion: what makes the difference? Liver Transpl 13 2007 773
    • (2007) Liver Transpl , vol.13 , pp. 773
    • Schmidt, H.1    Brockmann, J.2
  • 7
    • 33847758317 scopus 로고    scopus 로고
    • One year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients
    • H.T. Silva Jr, H.C. Yang, and M. Abouljoud One year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients Am J Transplant 7 2007 595
    • (2007) Am J Transplant , vol.7 , pp. 595
    • Silva Jr., H.T.1    Yang, H.C.2    Abouljoud, M.3
  • 8
    • 49849102947 scopus 로고    scopus 로고
    • Randomized trial of mycophenolate mofetil versus enteric- coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: One year follow-up
    • G. Ciancio, G.W. Burke, and J.J. Gaynor Randomized trial of mycophenolate mofetil versus enteric- coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up Transplantation 86 2008 67
    • (2008) Transplantation , vol.86 , pp. 67
    • Ciancio, G.1    Burke, G.W.2    Gaynor, J.J.3
  • 9
    • 0036424769 scopus 로고    scopus 로고
    • Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation
    • D. Cattaneo, N. Perico, and F. Gaspari Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation Kidney Int 62 2002 1060
    • (2002) Kidney Int , vol.62 , pp. 1060
    • Cattaneo, D.1    Perico, N.2    Gaspari, F.3
  • 10
    • 77649116838 scopus 로고    scopus 로고
    • Mycophenolate mofetil versus enteric-coated mycophenolate sodium: A large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients
    • H.W. Sollinger, A.K. Sundberg, and G. Leverson Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients Transplantation 89 2010 446
    • (2010) Transplantation , vol.89 , pp. 446
    • Sollinger, H.W.1    Sundberg, A.K.2    Leverson, G.3
  • 11
    • 1342325540 scopus 로고    scopus 로고
    • Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study
    • K. Budde, J. Curtis, and G. Knoll Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study Am J Transplant 4 2004 237
    • (2004) Am J Transplant , vol.4 , pp. 237
    • Budde, K.1    Curtis, J.2    Knoll, G.3
  • 12
    • 0034093785 scopus 로고    scopus 로고
    • Intravenous mycophenolate mofetil: Safety, tolerability, and pharmacokinetics
    • M.D. Pescovitz, D. Conti, and J. Dunn Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics Clin Transplant 14 2000 179
    • (2000) Clin Transplant , vol.14 , pp. 179
    • Pescovitz, M.D.1    Conti, D.2    Dunn, J.3
  • 13
    • 68949212932 scopus 로고    scopus 로고
    • Use of mycophenolate sodium in stable renal transplant recipients in Spain: Preliminary results of the MIDATA study
    • A. Snchez-Fructuoso, J.C. Ruiz, and M. Rengel Use of mycophenolate sodium in stable renal transplant recipients in Spain: preliminary results of the MIDATA study Transplant Proc 41 2009 2309
    • (2009) Transplant Proc , vol.41 , pp. 2309
    • Snchez-Fructuoso, A.1    Ruiz, J.C.2    Rengel, M.3
  • 14
    • 67651160692 scopus 로고    scopus 로고
    • Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation
    • M. Shehata, S. Bhandari, and G. Venkat-Raman Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation Transpl Int 22 2009 821
    • (2009) Transpl Int , vol.22 , pp. 821
    • Shehata, M.1    Bhandari, S.2    Venkat-Raman, G.3
  • 15
    • 33846105370 scopus 로고    scopus 로고
    • Comparison of enteric-coated mycophenolate sodium with mycophenolate mofetil in living renal allograft transplantation
    • M. Minz, A. Sharma, and M. Heer Comparison of enteric-coated mycophenolate sodium with mycophenolate mofetil in living renal allograft transplantation Transplant Proc 38 2006 2041
    • (2006) Transplant Proc , vol.38 , pp. 2041
    • Minz, M.1    Sharma, A.2    Heer, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.